147 related articles for article (PubMed ID: 11022714)
1. [Adverse reaction of LH-RH agonist and its countermeasure].
Oishi K
Nihon Rinsho; 2000 Jul; 58 Suppl():202-5. PubMed ID: 11022714
[No Abstract] [Full Text] [Related]
2. [Time to normalization of testosterone after withdrawal of long time LH-RH agonist therapy in prostate cancer].
Kaku H; Tsushima T; Nasu Y; Kumon H
Nihon Rinsho; 2002 Dec; 60 Suppl 11():182-7. PubMed ID: 12599568
[No Abstract] [Full Text] [Related]
3. [Characteristics, effects, side effects of the LH-RH agonist].
Miyanaga N; Akaza H
Nihon Rinsho; 2002 Dec; 60 Suppl 11():177-81. PubMed ID: 12599567
[No Abstract] [Full Text] [Related]
4. Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer.
Curry EA; Sweeney CJ
J Urol; 2002 Jul; 168(1):193. PubMed ID: 12050525
[No Abstract] [Full Text] [Related]
5. [Skin reaction induced by subcutaneous injection of LH-RH analogue].
Segawa N; Nishida T; Hamada S; Azuma H; Katsuoka Y; Nozaki K; Tsuji M
Hinyokika Kiyo; 2007 Oct; 53(10):695-8. PubMed ID: 18018584
[TBL] [Abstract][Full Text] [Related]
6. [Long-acting depot of LH-RH agonist].
Akaza H
Nihon Rinsho; 2000 Jul; 58 Suppl():309-11. PubMed ID: 11022737
[No Abstract] [Full Text] [Related]
7. Goserelin and locally advanced prostate cancer: new indication. Pros and cons.
Prescrire Int; 2000 Jun; 9(47):75-6. PubMed ID: 11010743
[TBL] [Abstract][Full Text] [Related]
8. [Goserelin acetate depot, LH-RH agonist; its properties and therapeutic effects in prostate cancer].
Koga H; Naito S
Nihon Rinsho; 2000 Jul; 58 Suppl():186-90. PubMed ID: 11022711
[No Abstract] [Full Text] [Related]
9. Final report on low-dose estramustine phosphate (EMP) monotherapy and very low-dose EMP therapy combined with LH-RH agonist for previously untreated advanced prostate cancer.
Kitamura T; Suzuki M; Nishimatsu H; Kurosaki T; Enomoto Y; Fukuhara H; Kume H; Takeuchi T; Miao L; Jiangang H; Xiaoqiang L
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S34-40. PubMed ID: 20094950
[TBL] [Abstract][Full Text] [Related]
10. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
Daskivich TJ; Oh WK
Urology; 2006 May; 67(5):1084.e15-7. PubMed ID: 16698377
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
Int J Urol; 2006 Jan; 13(1):87-8. PubMed ID: 16448441
[TBL] [Abstract][Full Text] [Related]
12. Granulomas induced by subcutaneous injection of leuprorelin acetate.
Sakamoto R; Higashi Y; Mera K; Kanekura T; Kanzaki T
J Dermatol; 2006 Jan; 33(1):43-5. PubMed ID: 16469084
[TBL] [Abstract][Full Text] [Related]
13. Dermatitis herpetiformis associated with administration of a gonadotropin-releasing hormone analog.
Yu SS; Connolly MK; Berger TG; McCalmont TH
J Am Acad Dermatol; 2006 Feb; 54(2 Suppl):S58-9. PubMed ID: 16428002
[No Abstract] [Full Text] [Related]
14. Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection.
Montgomery BS; Borwell JP; Higgins DM
Prostate Cancer Prostatic Dis; 2005; 8(1):66-8. PubMed ID: 15700050
[TBL] [Abstract][Full Text] [Related]
15. [The effective therapy of the hot flashes during hormone withdrawal treatment in patients with advanced prostatic carcinoma].
Kliesch S; Behre HM; Roth S
Dtsch Med Wochenschr; 1997 Jul; 122(30):940-5. PubMed ID: 9280708
[No Abstract] [Full Text] [Related]
16. [Bone fracture receiving LH-RH agonists for prostatic cancer].
Hatano T; Igarashi H; Nakada J; Oishi Y; Yanada S; Furuta A; Takizawa A; Iwamuro S; Tashiro K
Nihon Hinyokika Gakkai Zasshi; 2000 Jun; 91(6):542-6. PubMed ID: 10897579
[TBL] [Abstract][Full Text] [Related]
17. Randomised crossover trial to assess the tolerability of LHRH analogue administration.
Williams G; Lindsay S; Bowsher WG
Prostate Cancer Prostatic Dis; 2003; 6(2):187-9. PubMed ID: 12806381
[TBL] [Abstract][Full Text] [Related]
18. Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer.
Miyaji Y; Saika T; Yamamoto Y; Kusaka N; Arata R; Ebara S; Nasu Y; Tsushima T; Kumon H
Urology; 2004 Jul; 64(1):128-31. PubMed ID: 15245949
[TBL] [Abstract][Full Text] [Related]
19. Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer.
Ulloa EW; Salup R; Patterson SG; Jacobsen PB
Psychooncology; 2009 Jun; 18(6):598-605. PubMed ID: 18942660
[TBL] [Abstract][Full Text] [Related]
20. Incidence rate of injection-site granulomas resulting from the administration of luteinizing hormone-releasing hormone analogues for the treatment of prostatic cancer.
Shiota M; Tokuda N; Kanou T; Yamasaki H
Yonsei Med J; 2007 Jun; 48(3):421-4. PubMed ID: 17594149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
